The ICAD chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ICAD chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The ICAD stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View ICAD Detailed Price Forecast - CNN Money||View ICAD Detailed Summary - Google Finance|
|View ICAD Detailed Summary - Yahoo! Finance||View ICAD Stock Research & Analysis - Zacks.com|
|View ICAD Trends & Analysis - Trade-Ideas||View ICAD Major Holders - Barrons|
|View ICAD Call Transcripts - NASDAQ||View ICAD Breaking News & Analysis - Seeking Alpha|
|View ICAD Annual Report - CompanySpotlight.com||View ICAD OTC Short Report - OTCShortReport.com|
|View ICAD Fundamentals - TradeKing||View ICAD SEC Filings - Bar Chart|
|View Historical Prices for ICAD - The WSJ||View Performance/Total Return for ICAD - Morningstar|
|View the Analyst Estimates for ICAD - MarketWatch||View the Earnings History for ICAD - CNBC|
|View the ICAD Earnings - StockMarketWatch||View ICAD Buy or Sell Recommendations - MacroAxis|
|View the ICAD Bullish Patterns - American Bulls||View ICAD Short Pain Metrics - ShortPainBot.com|
|View ICAD Stock Mentions - StockTwits||View ICAD Stock Mentions - PennyStockTweets|
|View ICAD Stock Mentions - Twitter||View ICAD Investment Forum News - Investor Hub|
|View ICAD Stock Mentions - Yahoo! Message Board||View ICAD Stock Mentions - Seeking Alpha|
|View Insider Transactions for ICAD - SECform4.com||View Insider Transactions for ICAD - Insider Cow|
|View ICAD Major Holdings Summary - CNBC||View Insider Disclosure for ICAD - OTC Markets|
|View Insider Transactions for ICAD - Yahoo! Finance||View Institutional Holdings for ICAD - NASDAQ|
|View ICAD Stock Insight & Charts - FinViz.com||View ICAD Investment Charts - StockCharts.com|
|View ICAD Stock Overview & Charts - BarChart||View ICAD User Generated Charts - Trading View|
NASHUA, N.H., Jan. 07, 2019 (GLOBE NEWSWIRE) -- iCAD, Inc. (ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the results of a long-term study conducted at Hoag Memorial Hospital Presbyterian with the Xoft® Axxent® Electronic Brachytherapy (eBx®) System® for the treatment of early-stage breast cancer using intraoperative radiation therapy (IORT). With a median follow-up of 36 months, outcomes published in the Annals of Surgical Oncology showed that breast cancer recurrence rates of patients who were treated with IORT using the Xoft System were comparable to those seen in the cornerstone, randomized TARGIT-A and ELIOT trials, which evaluated IORT using different technology.
Arcturus Therapeutics Appoints Andrew Sassine as Chief Financial Officer
Posted on Thursday January 03, 2019
SAN DIEGO, Jan. 03, 2019 -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading RNA medicines company focused on the development and commercialization of therapeutics towards.
iCAD Announces CFO Transition
Posted on Thursday December 27, 2018
NASHUA, N.H., Dec. 27, 2018 (GLOBE NEWSWIRE) -- iCAD, Inc. (ICAD), a global medical technology company providing innovative cancer detection and therapy solutions, today announced that Richard Christopher, Executive Vice President, Chief Financial Officer, is resigning from the Company to pursue another career opportunity, effective January 11, 2019. Mr. Christopher’s resignation is not the result of any dispute or disagreement with iCAD or any matter relating to the Company’s accounting practices or financial statements.
iCAD, Inc. Announces $7.0 Million Private Placement of Unsecured Subordinated Convertible Debentures
Posted on Thursday December 20, 2018
NASHUA, N.H., Dec. 20, 2018 (GLOBE NEWSWIRE) -- iCAD, Inc. (ICAD), a global medical technology company providing innovative cancer detection and therapy solutions, today announced that it has entered into definitive agreements to sell unsecured subordinated convertible debentures, due three years following issuance, to certain institutional and accredited investors, including participation by all directors and executive officers of iCAD, in a private placement with gross proceeds of approximately $7.0 million. iCAD expects to close the sale of the debentures on or about December 21, 2018, subject to the satisfaction of customary closing conditions. With the recent U.S. FDA clearance of ProFound AI for mammography, a high-performance, cancer detection AI technology, the company will have added funds to bolster its commercial capability in what is a substantial addressable market.